Lensar (LNSR) Liabilities and Shareholders Equity (2019 - 2026)
Lensar's (LNSR) quarterly Liabilities and Shareholders Equity came in at $66.2 million in Q1 2026, down 9.23% year-on-year from $73.0 million in Q1 2025, and down 7.29% on a QoQ basis from $71.4 million in Q4 2025.
Lensar (LNSR) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Lensar (LNSR) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $66.2 million in Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 9.23% year-over-year to $66.2 million in Q1 2026; TTM through Mar 2026 was $278.3 million, a 5.93% increase from a year earlier, with the FY2025 full-year figure at $71.4 million, up 7.74% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $66.2 million, down from $71.4 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for LNSR reached as high as $73.0 million in Q1 2025 and fell as low as $52.0 million in Q1 2023.
- Historically, Liabilities and Shareholders Equity has averaged $64.7 million across 5 years, with a median of $66.2 million in 2026.
- Across the five-year window, Liabilities and Shareholders Equity retreated 19.53% in 2022 and grew 29.29% in 2023, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $55.8 million in 2022, then grew by 24.61% to $69.6 million in 2023, then dropped by 4.73% to $66.3 million in 2024, then increased by 7.74% to $71.4 million in 2025, then slipped by 7.29% to $66.2 million in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $66.2 million in Q1 2026, $71.4 million in Q4 2025, and $70.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 6.63 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 31.92 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 37.13 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 10.46 Bn |
| 10 | Lensar | 70.05 Mn | 72.73 Mn | 6.38 Mn | 66.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.22 Mn |
| Dec 31, 2025 | 71.43 Mn |
| Sep 30, 2025 | 70.20 Mn |
| Jun 30, 2025 | 70.41 Mn |
| Mar 31, 2025 | 72.96 Mn |
| Dec 31, 2024 | 66.30 Mn |
| Sep 30, 2024 | 62.02 Mn |
| Jun 30, 2024 | 61.41 Mn |
| Mar 31, 2024 | 66.13 Mn |
| Dec 31, 2023 | 69.59 Mn |
| Sep 30, 2023 | 70.85 Mn |
| Jun 30, 2023 | 71.20 Mn |
| Mar 31, 2023 | 51.96 Mn |
| Dec 31, 2022 | 55.84 Mn |
| Sep 30, 2022 | 54.80 Mn |
| Jun 30, 2022 | 58.70 Mn |
| Mar 31, 2022 | 60.30 Mn |
| Dec 31, 2021 | 66.47 Mn |
| Sep 30, 2021 | 68.10 Mn |
| Jun 30, 2021 | 72.48 Mn |